Prosecution Insights
Last updated: October 04, 2026

Fresenius Kabi Austria GmbH

Technology area: Biotechnology & Pharmaceuticals

4 pending office actions • 2 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days

Analysis

Fresenius Kabi Austria GmbH currently manages 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. This workload is distributed across 4 distinct examiners, which indicates the portfolio is not overseen by an individual. The prosecution activity is located within 2 distinct art units, showing the technical scope of these filings. Practitioners should note the ratio of examiners to art units, as this may lead to varied examination styles within the specified technology area.

OLSEN, KAELEIGH ELIZABETH is identified as the busiest examiner for the company, and she is responsible for 1 pending office action. This distribution shows that no individual examiner holds all pending matters, as the actions are split among the distinct examiners. The presence of 2 distinct art units suggests that while the examiners are different, they operate within a limited number of departments. This balance between multiple examiners and the art units requires a strategy that accounts for individual examiner tendencies while maintaining consistency across the portfolio.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

4
Total Pending OAs
4
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

4
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Multi-statute (no §101)4 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

3
Life Sciences
75% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
1
Business / Other
25% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

40 h
Manual time on pending OAs
8 h
Time saved (low, 20%)
14 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
OLSEN, KAELEIGH ELIZABETH 1 50.0% +61.5%
KWON, YONG SOK 1 24.6% +42.7%
O DELL, DAVID K 1 57.7% +36.0%
WHEELER, THURMAN MICHAEL 1 45.8% +23.5%

Hard Cases (4)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
18715677 EPHEDRINE LIQUID FORMULATIONS OLSEN, KAELEIGH ELIZABETH —
18705423 PHYTONADIONE FOR PARENTERAL ADMINISTRATION KWON, YONG SOK —
18572334 AQUEOUS, ROOM-TEMPERATURE STABLE ROCURONIUM COMPOSITION O DELL, DAVID K —
17787478 METHODS FOR PRODUCING OIL-IN-WATER EMULSIONS WHEELER, THURMAN MICHAEL —

Interview Candidates (4)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
18715677 EPHEDRINE LIQUID FORMULATIONS OLSEN, KAELEIGH ELIZABETH —
18705423 PHYTONADIONE FOR PARENTERAL ADMINISTRATION KWON, YONG SOK —
18572334 AQUEOUS, ROOM-TEMPERATURE STABLE ROCURONIUM COMPOSITION O DELL, DAVID K —
17787478 METHODS FOR PRODUCING OIL-IN-WATER EMULSIONS WHEELER, THURMAN MICHAEL —

Top Art Units

Art UnitApps
1619 2
1621 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18715677 EPHEDRINE LIQUID FORMULATIONS OLSEN, KAELEIGH ELIZABETH 1619 §103§112 Non-Final OA — Pending May 31, 2024
18705423 PHYTONADIONE FOR PARENTERAL ADMINISTRATION KWON, YONG SOK — §103§112 Non-Final OA — Pending Apr 26, 2024
18572334 AQUEOUS, ROOM-TEMPERATURE STABLE ROCURONIUM COMPOSITION O DELL, DAVID K 1621 §102§103§112 Non-Final OA — Pending Dec 20, 2023
17787478 METHODS FOR PRODUCING OIL-IN-WATER EMULSIONS WHEELER, THURMAN MICHAEL 1619 §103§112 Non-Final OA — Pending Jun 20, 2022

Managing Fresenius Kabi Austria GmbH's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month